Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIV200 Vaccine in Platinum-Sensitive Ovarian Cancer
NCT02978222Phase 2Terminated
- Sponsor
- Marker Therapeutics, Inc.
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TPIV200 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Marker Therapeutics, Inc. Primary endpoint: Progression Free Survival at 2 years. Started Jul 2017; status: terminated.
02
Drugs
TPIV200
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02978222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978222.